Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
about
Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migrationProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaEndogenous inhibitor proteins that connect Ser/Thr kinases and phosphatases in cell signaling.The Rac1 hypervariable region in targeting and signaling: a tail of many storiesThe Basic Biology of PP2A in Hematologic Cells and MalignanciesSignaling and stress: The redox landscape in NOS2 biologyProtein Ser/Thr phosphatases--the ugly ducklings of cell signalling.Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancerErlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoproteinSubcellular proteomics reveals a role for nucleo-cytoplasmic trafficking at the DNA replication origin activation checkpointCracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic virusesTherapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid LeukemiaViewing serine/threonine protein phosphatases through the eyes of drug designersIdentification of miR-145 targets through an integrated omics analysis.SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsDiscovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.The N-terminal Set-β Protein Isoform Induces Neuronal DeathOverexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.Human apolipoprotein E genotypes differentially modify house dust mite-induced airway disease in miceOverexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2AStable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Protein phosphatase 2A: a target for anticancer therapy.PP2A-Mediated Anticancer Therapy.OP449 inhibits breast cancer growth without adverse metabolic effects.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line.Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015).Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation.
P2860
Q24305121-2222C1FD-FB74-4CA5-AF8D-C0C42E70719AQ26752430-033CDEA4-AA5B-4A75-9F54-F5C6608844AAQ26849244-6C092417-0940-4EA8-83D3-9381066EBD6AQ26864271-497FA0C0-0701-4962-BC39-26668F3B91C0Q28088697-F890ABFF-12C7-4F89-9295-09E7E61372B9Q28833738-9D12B31C-6D01-4BD3-97E5-49F97E56F396Q30455386-65C9CABC-2106-4D98-AD23-EEC4910F2B47Q33835127-E258CA6E-C3C5-4887-AC21-595077150A79Q33977247-3440FEFB-6777-48FD-9F92-E58BE1D5F6B2Q34007879-3C274E76-5155-4B89-8A9F-8A8F50399B6AQ34555685-2E4FDCDF-ACDD-4EA4-895F-8F989EE28061Q34667732-7DC0A5D8-69CF-47A1-9F18-826F3A119CD9Q34730329-13481401-E32C-48E5-A786-A85B9EB99597Q34901718-A8FBFD51-8413-43A7-BAD5-0ABD060512BEQ35037262-C345C70C-97A3-4965-BDC7-BAC5DAA21222Q35146774-C5B4554F-02B4-4BBB-957F-0A36B6DEC069Q35155627-93C2F1FB-426F-4F13-B8D4-82D9243F24D6Q35483640-1BA171CD-B6F2-45CA-9B91-78B7A98BB531Q35552005-D0D3BD04-F9E5-4984-B933-AE7CFF371D60Q35828517-6485BDCD-D2C6-417C-AC14-89F81E243DBFQ35861000-20A834CF-3D02-441E-9ED5-45FFAB9EA694Q35944719-2438E2A6-7AFE-4AAB-A305-EF0D6E983233Q35950145-619A337F-E3A4-4FCC-B778-77C07E0C596FQ36020877-1D63E7FF-F8C2-4E5E-88DA-E2A91F5F14EFQ36050039-9562AF6F-B24E-4E3C-8C36-47F75B5BDD66Q36275673-CBCD1DAB-A71B-47CB-8C7D-AB93CF93D2D3Q36729492-2F1C8508-AB8A-4A3C-A199-007A94A42B89Q37607196-69A2D0C6-73A7-4659-9493-E5A6C5BC7B38Q37707099-CF04CEDE-9F47-4A23-8A2E-2BF09893D84DQ37708933-828A4F9D-BBBC-4B03-88DB-D9A19CBE4031Q38103646-2E58CEDE-81A4-4B40-B10E-9C359B30DB71Q38168831-E6C04400-1598-4486-B2C2-B9DFDDCFDFA4Q38613399-CD5A9F20-D119-4020-A714-794F985F517AQ38617799-2F99E337-BFD4-4872-9AE8-E812B59BCC77Q38678579-E452EF87-D4D7-428E-A69D-A7F111BCC97AQ38699543-B5EB680A-3F4B-4F13-A286-BD3D1874E974Q38725557-F12A1A3A-6E39-4A91-854E-002210E85854Q38904928-DC085B11-F646-40B9-A4A8-1032EB8136ABQ39097201-C9ECED9B-B9E9-4956-9BF0-7D21318E3AF8Q39333626-F95492C3-7E99-4C22-B9B3-6255C664B4A0
P2860
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@ast
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@en
type
label
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@ast
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@en
prefLabel
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@ast
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@en
P2093
P2860
P356
P1433
P1476
Targeting SET/I(2)PP2A oncopro ...... ay strategy for cancer therapy
@en
P2093
C H Switzer
D J Christensen
P2860
P2888
P304
P356
10.1038/ONC.2010.622
P407
P577
2011-02-07T00:00:00Z